°Ë»ö
ä¿ë
Á¤º¸
    LSK±Û·Î¹úPS, 'Çõ½ÅÀû ¹Ì·¡ ÀÓ»ó½ÃÇè ½ÉÆ÷Áö¾ö' ³»´Þ °³ÃÖ
    ±â»çÀÔ·Â : 23.02.28 09:22:28
    0 °¡
    ÇÃÄ£Ãß°¡

    "ÀÓ»ó½ÃÇè ȯ°æ ´ë°Ýº¯ ¼Ó, Â÷¼¼´ë ´ëÀÀÃ¥ Á¦½Ã"


     ¡ãLSK±Û·Î¹úPS°¡ ¿À´Â 3¿ù 9ÀÏ ¼­¿ï µå·¡°ï ½ÃƼ ±×·£µå º¼·ë ÇѶ󿡼­ ¹Ì·¡ ÀÓ»ó½ÃÇèÀ» ÁÖÁ¦·Î ½ÉÆ÷Áö¾öÀ» °³ÃÖÇÑ´Ù.(ÀÚ·á LSK±Û·Î¹úPS)


    [µ¥Àϸ®ÆÊ=ȲÁøÁß ±âÀÚ] ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO) LSK±Û·Î¹úPS´Â ¿À´Â 3¿ù9ÀÏ ¼­¿ï ¿ë»ê±¸¿¡ ÀÖ´Â ¼­¿ïµå·¡°ï½ÃƼ¿¡¼­ Äڷγª19·Î º¯È­µÈ ±Û·Î¹ú ÀÓ»ó½ÃÇè µ¿Çâ°ú Çõ½ÅÀû ¹Ì·¡ ÀÓ»ó½ÃÇè ¼Ö·ç¼ÇÀ» ¼Ò°³ÇÏ´Â 'Çõ½ÅÀû ¹Ì·¡ ÀÓ»ó½ÃÇè ½ÉÆ÷Áö¾ö'À» °³ÃÖÇÑ´Ù°í 28ÀÏ ¹àÇû´Ù.

    LSK±Û·Î¹úPS´Â À̹ø ½ÉÆ÷Áö¾öÀ» ÅëÇØ º¯È­ÇÏ´Â ÀÓ»ó½ÃÇè ȯ°æÀ» Á¶¸íÇÏ°í ±×°£ ½×¾Æ¿Â ¾ÆÀ̵ð¾î¿Í ÇâÈÄ ÀÓ»ó½ÃÇè ¹æÇ⼺À» ³íÀÇÇÒ ¿¹Á¤ÀÌ´Ù.

    À̹ø ½ÉÆ÷Áö¾öÀº ¡ãÀÓ»ó½ÃÇèÀÇ »õ·Î¿î ÆÐ·¯´ÙÀÓ(New paradigm), ¡ãÀÓ»ó½ÃÇèÀÇ ÁøÈ­(The evolution of clinical trials), ¡ãÀÓ»ó½ÃÇèÀ» À§ÇÑ »õ·Î¿î ±â¼ú(New technologies for clinical trials) ÃÑ 3°³ ¼¼¼ÇÀ¸·Î ¿î¿µµÈ´Ù.

    ÀÓ»ó½ÃÇèÀÇ Çõ½ÅÀû ¹æ¹ý·Ð(Innovative Methodologies: Clinical Trials), ½Ç»ç¿ëµ¥ÀÌÅ͸¦ Ȱ¿ëÇÑ ½Å¾à°³¹ßÀÇ Çõ½ÅÀû ¹æ¹ý·Ð(Innovative Methodologies: Using Real-World Data in Drug Development), ±Û·Î¹ú °æÁ¦ ºÒȲ ¼Ó ÇØ°á°úÁ¦(Challenges of Global Economic Recession), ÀÓ»ó½ÃÇèÀÇ ±Û·Î¹ú Æ®·»µå(Global Trend of Clinical Trial), ±¹Á¦ÀÓ»óµ¥ÀÌÅÍÇ¥ÁØÄÁ¼Ò½Ã¾ö(CDISC)ÀÇ µ¥ÀÌÅÍ Ç¥ÁØ ¹× ºÐ¼® ±â¹ý(CDISC Data Standards and Analysis Techniques) µî ÃÑ 10°³ÀÇ °­ÀÇ·Î ±¸¼ºµÆ´Ù.

    °­¿¬Àڷδ LSK±Û·Î¹úPSÀÇ ³»ºÎ Àü¹®°¡»Ó¸¸ ¾Æ´Ï¶ó, ¹Ì±¹ ÅØ»ç½º´ëÇб³ »ç¿ì½º¿þ½ºÅϺ´¿ø(University of Texas Southwestern Medical Center) ¾Èö¿ì ¹Ú»ç¿Í ±¹°¡½Å¾à°³¹ß»ç¾÷´Ü(KDDF) ¹¬Çö»ó ´ÜÀå, ¼­¿ï´ëÇб³ ±è¿ë´ë ±³¼ö, ¾ÆÀÌÅ¥ºñ¾Æ(IQVIA) Á¤¼ö¿ë ´ëÇ¥ µî ±¹³»¿Ü Á¦¾à¹ÙÀÌ¿À ¾÷°è Àü¹®°¡µéÀÌ Âü¿©ÇÒ ¿¹Á¤ÀÌ´Ù.

    À̹ø ½ÉÆ÷Áö¾öÀº Á¦¾à¹ÙÀÌ¿À »ê¾÷ °ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÁøÇàµÈ´Ù. »ó¼¼ ¾ÆÁ¨´Ù ¹× »çÀüµî·Ï Á¤º¸´Â LSK±Û·Î¹úPS ȨÆäÀÌÁö¿¡¼­ È®ÀÎÀÌ °¡´ÉÇÏ´Ù.
    X
    AD
    ½ÅÁ¦Ç° ·±Äª À̺¥Æ® À̺¥Æ®Âü¿© ¡æ
    ȲÁøÁß ±âÀÚ(jin@dailypharm.com)
    ±ÛÀÚÅ©±â ¼³Á¤
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    °¡³ª´Ù¶ó¸¶¹Ù»ç
    • °æ³² ÇÔ¾È Ç°Áú°ü¸®¾à»ç ½ÅÀÔ/°æ·Â ä¿ë ¹Ù·Î°¡±â
    • ¿¬±¸°³¹ßº»ºÎ ÀÓ»óPM (°æ·Â 3³â¡è) ä¿ë ¹Ù·Î°¡±â
    • È­¼º Çâ³² Á¦Á¶°ü¸®¾à»ç (°æ·Â 7³â¡è) ä¿ë ¹Ù·Î°¡±â
    • º¹»ê³ªÀ̽º ºÎ»ê°ü¸®¾à»ç (ºÎ»êÅëÇÕ¹°·ù¼¾ÅÍ) ¹Ù·Î°¡±â
    • º´¿ø¿µ¾÷(MR) ä¿ë¿¬°èÇü ÀÎÅÏ(½ÅÀÔ»ç¿ø) ¸ðÁý °ø°í ¹Ù·Î°¡±â
    • [¹ÙÀÌ¿¤ÄÚ¸®¾Æ] MSL Ophthalmology (ÀÇÇкΠÁ¤±ÔÁ÷ ä¿ë) ¹Ù·Î°¡±â
    • [Çѵ¶] Digital Healthcare ¿µ¾÷, Á¦Á¶°ü¸® ¾à»ç, °æ¿µ°ü¸®, Power BI Specialist, Ãѹ«, ¾à¹°°¨½Ã, »ý»ê±âȹ ¹Ù·Î°¡±â
    • Á¤±ÔÁ÷ ¾à¹«Á÷(ÆÀÀå) ¾à»ç ä¿ë °ø°í ¹Ù·Î°¡±â
    • [Çѱ¹·Î½´Áø´Ü] MSA Manager Á¤±ÔÁ÷ ä¿ë ¹Ù·Î°¡±â
    • °³¹ß±âȹÆÀ_BD (°æ·Â 7³â¡è) ä¿ë ¹Ù·Î°¡±â
    • ÃæºÏ À½¼º °ü¸®¾à»ç(Á¦Á¶/ǰÁú) °æ·Â¹«°ü ¹Ù·Î°¡±â
    • Senior Specialist, PV, Drug Saftey ¹Ù·Î°¡±â
    • ǰÁúº¸ÁõÆÀÀå, ǰÁú°ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â
    • HK À̳뿣 °ü¸®¾à»ç(ÃæºÏ) / Çмú¾à»ç(°æ±â) ¸ðÁý ¹Ù·Î°¡±â
    0/300
     
    ¸ÞÀϺ¸³»±â
    ±â»çÁ¦¸ñ : LSK±Û·Î¹úPS, Çõ½ÅÀû ¹Ì·¡ ÀÓ»ó½ÃÇè ½ÉÆ÷Áö¾ö ³»´Þ °³ÃÖ